Current evidence for adjuvant, neoadjuvant, and perioperative systemic treatment for resectable non-small cell lung cancer is summarized and a practical approach to treatment selection is proposed.
Abstract
Simple Summary Treatment options for resectable non-small cell lung cancer have expanded substantially with the introduction of targeted therapies and immune checkpoint inhibitors. This review summarizes current evidence for adjuvant, neoadjuvant, and perioperative systemic treatment and proposes a practical approach to treatment selection. Surgery remains central to curative treatment, particularly for early-stage disease, while perioperative chemoimmunotherapy is increasingly relevant for stage II–III disease, especially in patients with N2 involvement. Molecular alterations such as EGFR mutations and ALK rearrangements guide the use of adjuvant targeted therapy, whereas PD-L1 expression can inform adjuvant immunotherapy decisions. Emerging biomarkers, including pathological response, residual viable tumor, and circulating tumor DNA, may further help individualize treatment but their utility for guiding decisions requires prospective validation.
The treatment of early-stage non-small-cell lung cancer (NSCLC) has evolved substantially in recent years. For decades, curative-intent surgery followed by platinum-based chemotherapy remained the standard of care (SOC), despite delivering only modest gains in long-term survival. Current evidence from randomised trials...
Jordi Remon, T. Cascone, S. P. Saw et al.· The Lancet Respiratory Medic...· 2 citations
The concept of personalized medicine has tremendous appeal—tailoring diagnosis and treatment to an individual, rather than a “one-size-fits-all” approach. The management of non-small-cell lung cancer (NSCLC) has rapidly evolved toward strategies increasingly guided by tumor biology and precision oncology. The safety an...
Emily P. Rabinovich, Linda W. Martin· Journal of Clinical Medicine· 0 citations
Uniform timing definitions, an explicit hierarchy separating direct evidence from extrapolation, and tumor-specific rather than universal rules for checkpoint inhibitor re-exposure are proposed for checkpoint inhibitor re-exposure.
F. Petrelli, L. Dottorini, A. Ghidini et al.· Current Oncology· 0 citations
Simple Summary Immunotherapy has changed the treatment of several gynecologic cancers, but its benefit varies greatly between tumor types and clinical settings. The clearest benefits are seen when treatment is matched to tumor biology, such as mismatch repair deficiency in endometrial cancer or PD-L1 expression in sele...
Chen Yang, Yu-Xiao Wu, Jun-Jun Yang et al.· Cancers· 0 citations
Stage III non-small cell lung cancer (NSCLC) is a highly heterogeneous disease, and recent phase III trials have demonstrated the efficacy of neoadjuvant and perioperative chemoimmunotherapy in selected patients. However, translating these data into consistent real-world multidisciplinary decision-making remains challe...
İ. Yıldız, Elif Şenocak Taşçı, F. Ağaoğlu· Frontiers in Oncology· 0 citations
BACKGROUND
The prognosis of metastatic nasopharyngeal carcinoma (mNPC) remains dismal despite recent advances of locoregional and systemic therapy. The incorporation of programmed death-1 (PD-1) inhibitors into first-line chemotherapy has transformed the therapeutic landscape; however, optimal treatment strategies beyo...
Wei-Jie Wen, Ji-Shi Li, Yuan-Mei Qu et al.· Cancer Treatment Reviews· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
